



GENSET.045A

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Blumenfeld, et al.

Appl. No. : 09/416,384

Filed : Oct 12, 1999

For : GENES, PROTEINS, AND
BIALLELIC MARKERS
RELATED TO CENTRAL
NERVOUS SYSTEM DISEASE

Examiner : Fredman, J.

) Group Art Unit 1655

) I hereby certify that this correspondence and all
) marked attachments are being deposited with
) the United States Postal Service as first-class
) mail in an envelope addressed to: Assistant
) Commissioner for Patents, Washington, D.C.
) 20231, on

September 25, 2000

(Date)

Daniel Hart, Reg. No. 40,637

RESPONSE TO RESTRICTION REQUIREMENT AND PRELIMINARY AMENDMENTAssistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Restriction Requirement mailed July 25, 2000 in the above-identified application, Applicants hereby elect Group IV, containing claims 45 and 46, for examination. Applicants note that the elected claims encompass two highly related polypeptide species (SEQ ID No. 5 and SEQ ID No. 7), as indicated in the specification at page 117, lines 34-35, and at page 120, lines 18-20. The examiner did not indicate whether Applicants would be required to elect a particular species should Group IV be selected for examination. However, as a result of the high degree of identity between SEQ ID Nos. 5 and 7, Applicants maintain that the two sequences can be examined together without imposing a burden on the examiner. Should the examiner disagree, Applicants elect SEQ ID No. 5 for examination.

Additionally, Applicants respectfully request that the Examiner enter the following amendments prior to examination of the above-identified application on the merits.

IN THE SPECIFICATION:

10/02/2000 RWJUNG1 00000012 03416384

01 FC:102
02 FC:103
03 FC:104
04 FC:105700.00 02
350.00 03
250.00 02
100.00 02